Radient Pharmaceuticals Corporation fka RXPC

[Future Doc]

@ Gold I believe you made an error.

"The problem with the clincial trials is the company already knows how the test will perform. They have been working with the test for a year and in a conference call last year, they said it performed within the 5% FDA limit and no new FDA application would be needed."


You meant to say that the physical TEST hasn't changed more than 5%. That 5% change has absolutely nothing to do with the results or ability of the test. The results could be drastically better with only a 5% PHYSICAL change.

"We know from the previous FDA application that the specificity is not really 95% and the test errors 26% of the time when cancer is actually growing."

This is not the SAME test to which they are attributing the 95% sensitivity and specificity. The NEW test is supposed to be 95% sensitive and selective. You CANNOT use that OLD FDA submission (for the OLD test) to judge the NEW test.

Furthermore, that 95% specificity has no data at all behind it YET so it is difficult to make assumptions about whether that is an ACTUAL improvement or statistical manipulation. We'll have to wait for the Mayo data see if this NEW test really has the claimed 95% specificity and sensitivity.